• Favorable complete response rate with IPH 1101 associated with low-dose IL-2 in combination with rituximab
• Last trial of the clinical program for IPH 1101 completed in a context where new cancer immunotherapies are emerging
• In total, the drug candidate was administered to about 200 patients in six clinical trials with good safety and early signs of activity in HCV and NHL

A conference call was organized on Monday, June 14, 2010:
Final data on response rate for the Phase II trial with IPH 1101 in Follicular Lymphoma reported at the EHA meeting.

Replay: +33 (0)1 72 00 15 01 / ID: 270333#

The slideshow presented during the conference call is

available here

.